AChE-IN-59 (compound 3b) is an AChE inhibitor with an IC₅₀ value of 0.05 μM. It effectively inhibits Aβ1-42 aggregation, protects nerve cells, and penetrates the blood-brain barrier efficiently. AChE-IN-59 is suitable for Alzheimer's disease (AD) research [1].

AChE:0.05 μM, BChE:4.68 μM

AChE-IN-59 (compound 3b) inhibits ChEs activity at concentrations of 50/100/500/1000 μg/mL over 5 minutes, with IC50 values of 0.05 μM for AChE and 4.68 μM for BuChE, demonstrating selective inhibition of the AChE subtype [1]. Additionally, AChE-IN-59 exhibits strong in vitro antioxidant activity as indicated by FRAP and DPPH radical scavenging assays [1]. At 25 µM for 5 minutes, AChE-IN-59 shows no cytotoxic effects on SH-SY5Y cells [1]. In cell viability assays using SH-SY5Y cells at concentrations of 0/6.25/12.5/25/50/100 µM over 5 hours, the compound displays notable neuroprotective effects within the 6.25-25 µM range and does not compromise cell viability below 25 µM.

AChE-IN-59 (compound 3b) (25 μM, 3 day) has been shown to mitigate the locomotor retardation in zebrafish larvae induced by AlCl3 (5 mg/L) [1]. In this study, zebrafish larvae were utilized as the experimental animal model, with the compound administered through immersion at dosages of 5/10/25/50/100 μg/mL. The findings indicate that AChE-IN-59 offers therapeutic benefits against AlCl3-induced behavioral inhibition in zebrafish, with its efficacy enhancing progressively as the drug concentration increases, as evidenced by the gradual increase in the total distance moved by the larvae.